How the eye's light-control enzyme PDE6 and its helper proteins work

Regulation of Retinal cGMP-Phosphodiesterases

['FUNDING_R01'] · UNIVERSITY OF IOWA · NIH-11232336

This research looks at how a key eye enzyme and its helper proteins fold and switch on, which could help people with inherited retinal blindness such as retinitis pigmentosa or Leber congenital amaurosis.

Quick facts

Phase['FUNDING_R01']
Study typeNih_funding
SexAll
SponsorUNIVERSITY OF IOWA (nih funded)
Locations1 site (IOWA CITY, UNITED STATES)
Trial IDNIH-11232336 on ClinicalTrials.gov

What this research studies

Researchers are examining the molecular steps that let PDE6, an enzyme essential for converting light into signals in rod and cone cells, mature into a working form. They focus on how the chaperone proteins AIPL1 and HSP90 interact with PDE6 and use biochemical and structural methods to map the protein-protein interfaces and the complex's shape in solution. The team will use cell systems and animal models that mimic human disease mutations to follow PDE6 folding from a closed nonfunctional state through intermediate forms to the active open state. Findings will test a detailed model of how these helper proteins and regulatory subunits enable PDE6 to become functional and may reveal targets for therapy.

Who could benefit from this research

Good fit: People with genetically confirmed PDE6 or AIPL1 mutations causing inherited retinal degenerations (for example, retinitis pigmentosa, achromatopsia, or Leber congenital amaurosis) would be the most directly relevant candidates.

Not a fit: Patients whose vision loss is caused by unrelated conditions such as age-related macular degeneration or diabetic retinopathy are unlikely to benefit directly from this work.

Why it matters

Potential benefit: If successful, this work could identify steps to target with gene or drug therapies to preserve or restore photoreceptor function in people with inherited retinal degenerations.

How similar studies have performed: Previous laboratory studies have shown that AIPL1 and HSP90 are important for PDE6 maturation, but the precise folding pathway and how to target it therapeutically remain largely unproven.

Where this research is happening

IOWA CITY, UNITED STATES

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.

View on NIH RePORTER →

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.